Mersana Therapeutics 株価情報 (NASDAQ: MRSN)

最新ニュース Mersana Therapeutics (NASDAQ:MRSN) 株価情報

Mersana Therapeutics

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics Inc

WIIM

CHX stock has given up its prior gain. ChampionX shares were trading higher after the company reported better-than-expected Q1 adjusted EPS results.

VLTO

VLTO stock has given up its prior gain. Veralto shares were trading higher after the company reported better-than-expected Q1 financial results.

Small Cap Consumer Research analyst Eric Beder reiterates Jakks Pacific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAKK#NASDAQ">JAKK</a>) with a Buy and maintains $40 price target.

News

Price Target

Reiteration

Analyst Ratings

JAKK

Small Cap Consumer Research Reiterates Buy on Jakks Pacific, Maintains $40 Price Target

Robinhood Markets Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) will be reporting its first-quarter earnings on Wednesday. Wall Street expects 33 cents in EPS and $922.53 million in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=HOOD" target="_blank" rel="noreferrer noopener"> after market hours</a>.
The stock is up 199.39% over the past year, 25.18% YTD.
Let&#8217;s look at what the charts indicate for HOOD stock and how it maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/25/04/45057303/cathie-wood-chops-palantir-ark-invest-dumps-9-1-million-worth-of-stock-also-sells-meta-and-robinhood-shares">Cathie Wood Chops Palantir: Ark Invest Dumps $9.1 Million Worth Of Stock, Also Sells Meta And Robinhood Shares</a>
<h2 class="wp-block-heading">HOOD Stock Strongly Bullish Ahead Of Q1 Earnings&nbsp;</h2>
HOOD stock is displaying a technically strong bullish setup, with short- and long-term indicators aligning in the stock's favor.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0430"><img loading="lazy" decoding="async" width="627" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30080904/Screenshot-2025-04-30-at-4.10.52-PM.png" alt="" class="wp-image-894759" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30080904/Screenshot-2025-04-30-at-4.10.52-PM.png 627w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30080904/Screenshot-2025-04-30-at-4.10.52-PM-300x234.png 300w" sizes="(max-width: 627px) 100vw, 627px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0430" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
HOOD stock, at $49.37 &#8211; trades comfortably above its five, 20 and 50-day exponential moving averages, signaling solid upward momentum and continued buying pressure. The stock&#8217;s position above its eight-day simple moving average (SMA) of $45.46, 20-day SMA of $42.31 and 50-day SMA of $44.31 confirms the bullish trend.
From a longer-term perspective, HOOD remains firmly above its 200-day simple moving average of $34.67, reinforcing the strength of the rally. The Moving Average Convergence Divergence (MACD) reading of 1.34 suggests positive price momentum is still building. At the same time, the Relative Strength Index (RSI) at 60.85 indicates the stock is approaching &#8211; but hasn't yet entered &#8211; overbought territory.
For investors, this technical setup supports a bullish outlook, though some caution may be warranted if RSI creeps higher.
<h2 class="wp-block-heading">Robinhood Analysts See Over 15% Upside</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/HOOD/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> for Robinhood stock is currently Overweight, with a price target of $62 per share. The latest analyst calls from Keybanc, JMP and Barclays imply a 15.43% upside for Robinhood stock. Their average price target of $56.67 suggests confidence in HOOD's continued rally.
HOOD Price Action: Robinhood stock closed the trading day Tuesday at $49.37, up 0.90%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45078148/6-stocks-showing-momentum-as-the-market-rebounds">6 Stocks Showing Momentum As The Market Rebounds</a></li>
</ul>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Technicals

Previews

Markets

Trading Ideas

HOOD

Robinhood Stock Soars 199% In A Year - Can Q1 Earnings Keep The Rally Alive?

Etsy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETSY#NASDAQ">ETSY</a>) shares are <a href="https://www.benzinga.com/premarket">trading higher in premarket</a> on Wednesday after the e-commerce company released first-quarter 2025 earnings.
The company reported<a href="https://www.benzinga.com/pressreleases/25/04/n45095631/etsy-inc-reports-first-quarter-2025-results"> first-quarter sales growth of 0.8%</a> year-on-year to $651.18 million, beating the analyst consensus estimate of $642.67 million.
The revenue gain was due to growth in on-site advertising revenue for both Etsy and Depop, a full quarter impact of the seller set-up fee, and continued benefit from Payments expansion.
Consolidated GMS declined 6.5% to $2.8 billion. Adj EPS of 46 cents <a href="https://www.benzinga.com/earnings">missed the consensus </a>estimate of 49 cents.
Etsy marketplace GMS decreased 8.9% to&nbsp;$2.3 billion, a result of pressure on consumer discretionary product spending, challenging year-over-year comparisons in a shortened holiday season, category mix, and a highly promotional and competitive retail environment.
Also Read: <a href="https://www.benzinga.com/news/25/04/45074719/levi-strauss-shareholders-stand-by-dei-policy-amid-political-pushback">Levi Strauss Shareholders Stand By DEI Policy Amid Political Pushback</a>
Active buyers declined 3.4% to 88.5 million. GMS per active buyer on a trailing twelve-month basis slipped 3.5% to $120.
Gross profit for the quarter increased 0.1% to $459.11 million with a gross margin of 70.5%. Operating expenses for the quarter rose 23.2% to $481.442 million. 
Adjusted EBITDA improved 1.9% to $171.1 million and the corresponding EBITDA margin expanded 30 basis points to 26.3%.
As of March 31, the company held $649.1 million in cash and equivalents. Operating cash flow for the quarter totaled $49.18 million.
&#8220;We are keeping a clear eye on&nbsp;Etsy&#8217;s&nbsp;long-term opportunities, while also staying nimble in the face of uncertainty given recent tariff announcements and the fluid state of consumer confidence in our core markets,&#8221; said CFO Lanny&nbsp;Baker.
Outlook:&nbsp;Etsy expects second-quarter FY25 GMS to decline at a rate similar to, to potentially lightly better than the year-over-year&nbsp;performance reported for the fourth quarter of FY24.
The company expects second quarter adjusted EBITDA margin of about 25%.
Price Action: ETSY shares traded higher by 0.61% at $46.41 in premarket at last check Wednesday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/25/04/45078934/dominos-pizza-will-grow-with-stuffed-crust-doordash-partnership-say-analysts">Domino&#8217;s Pizza Will Grow With Stuffed Crust &amp; DoorDash Partnership, Say Analysts</a></li>
</ul>
Image: Shutterstock

Movers & Shakers

General

ETSY

Etsy 'Stays Nimble,' CEO Says As Revenue Grows, Active Buyers Decline

MNDR

Mobile-health Network Solutions Intends To Acquire Indopacific Health Technology And Its Subsidiaries; Terms Not Disclosed

On Wednesday, British multinational pharmaceutical GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) reported first-quarter sales of $9.46 billion (7.52 billion Sterling Pounds), up 2% year-over-year and 4% on constant currency. Analysts had <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">estimated sales of $7.46 billion</a>.
Vaccine sales fell 8% (-6% at constant currency) to 2.09 billion pounds, primarily impacted by lower demand for Arexvy related to a more limited ACIP recommendation and lower demand for Shingrix in the U.S. and International. Meningitis vaccines continued to show strong demand with double-digit sales growth.
Arexvy sales reached 78&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44876132/us-advisory-panel-votes-to-expand-recommendation-for-pfizer-gsks-rsv-vaccines-for-older-adults-below-60-years" rel="noreferrer noopener">million pounds, down 57%</a>. Meningitis vaccine <a target="_blank" href="https://www.gsk.com/en-gb/media/press-releases/gsk-makes-strong-start-to-2025-with-growth-in-sales-profits-and-earnings/" rel="noreferrer noopener">sales</a> increased 17% (+20%) to 350 million, while established vaccine sales of 799 million fell 5% (-3%).
<a target="_blank" href="https://www.benzinga.com/25/04/44634572/gsk-stock-is-trading-higher-as-new-study-shows-shingles-vaccine-linked-to-20-lower-dementia-risk" rel="noreferrer noopener">Shingrix sales</a> reached 867 million pounds, down 8% (-7% at constant currency).
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44496482/fda-approves-gsks-oral-antibiotic-for-urinary-tract-infections-for-females-aged-12-years-and-older" rel="noreferrer noopener">FDA Approves GSK&#8217;s Oral Antibiotic For Urinary Tract Infections For Females Aged 12 Years And Older</a>
Specialty Medicines sales grew by double-digit percentages (+16% and 17% on constant currency) in the quarter to 2.93 billion pounds, reflecting continued growth across disease areas, with strong performances in HIV, Respiratory, Immunology and Inflammation, and oncology.
General Medicines sales fell by 3% to&nbsp;2.49 billion pounds.
The company reported a core EPS of $1.13 (44.9 pence), beating the consensus of $1.04.
GSK plans to market five new specialty medicines this year, including the return of the previously withdrawn multiple <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44873982/uk-becomes-first-country-to-authorize-blenrep-in-two-combo-regimens" rel="noreferrer noopener">myeloma treatment Blenrep</a>.
Tariffs: GSK notes that the U.S. Administration has initiated an investigation under Section 232 of the Trade Expansion Act to determine the effects of <a target="_blank" href="https://www.benzinga.com/25/04/44724763/pharma-industry-faces-jitters-as-trump-hints-at-historic-tariffs-bofa-outlines-probable-timeline" rel="noreferrer noopener">pharmaceutical product imports</a> on national security.
The company is well positioned to respond to the potential financial impact of sector-specific tariffs, should they be implemented, with mitigation options identified in the supply chain and productivity initiatives.
Guidance:&nbsp;GSK reaffirms 2025 guidance and expects sales to grow between 3% and 5%, with core earnings per share and operating profit growing between 6% and 8%.
Specialty Medicine sales are expected to increase by a low double-digit percent, Vaccine revenue is expected to decline by a low single-digit percent, and general medicine sales are expected to be broadly stable.
Price Action:&nbsp;At last check on Wednesday, GSK stock was up 3.57% to $40.37 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/45080457/abeona-therapeutics-wins-fda-approval-for-first-of-its-kind-gene-therapy" target="_blank" rel="noreferrer noopener">Abeona Therapeutics Wins FDA Approval For First-of-Its-Kind Gene Therapy</a></li>
</ul>
Photo by HJBC via Shutterstock

Biotech

Earnings

Large Cap

Guidance

Eurozone

Health Care

Movers

Britain's GSK Asserts It Is 'Well Positioned' To Mitigate Potential Tariffs After Strong Q1 Cancer And HIV Drug Sales

Wall Street is set for a volatile Wednesday after first-quarter GDP data showed an unexpected economic contraction, stoking fears that a recession <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/45098824/tariffs-hit-hard-as-us-economy-shrinks-for-first-time-since-2022">may already be underway. </a>
The U.S. economy shrank by 0.3% on an annualized basis last quarter, down from 2.4% growth in the previous quarter and well below the expected 0.4% growth, official advance statistics showed.
The outcome marked the first quarterly contraction since the second quarter of 2022. 
In addition, U.S. private employers added 62,000 jobs in April, according to ADP National Employment Report, the lowest since July 2024 and well below predictions of 108,000. 
Broad-based equity losses followed during premarket trading in New York as investors digested signs of weakening growth, elevated inflation, and deteriorating trade balances.
Futures on the S&amp;P 500 fell 1.28% to 5,489.61 by 9:00 a.m. ET, shedding 71 points. 
Contracts on the Dow Jones Industrial Average declined by 336 points, or 0.8%, to 40,191. The tech-heavy Nasdaq 100 underperformed, plunging 1.9% to 19,184, while the small-cap Russell 2000 index dropped 1.7% to 1,944.
Recession odds for 2025 climbed to 74%, their highest level yet, according to data from CFTC-regulated betting platform Kalshi. Under Kalshi&#8217;s terms, a $100 bet on a recession now yields $131 if the U.S. sees two consecutive quarters of negative GDP growth.
<iframe loading="lazy" src="https://kalshi.com/external-widgets/events/RECSSNBER-25/markets/RECSSNBER-25?color_scheme=light&#038;widget_size=medium&#038;variant=a&#038;utm_campaign=benzinga_widget" width="488px" height="242px" style="border:0"></iframe>
<h3 class="wp-block-heading">Economists Divided On US Economic Performance</h3>
David Russell, global head of market strategy at TradeStation, noted the growing stagflation risk: "Today's data shows more stagflation, with the economy shrinking and prices rising more than expected. Trade was a huge drag as imports jumped ahead of tariffs. Combined with the weak ADP payrolls growth and yesterday's weak JOLTs data, the numbers increasingly suggest a recession may have begun."
Economist Joseph Brusuelas of RSM US LLP offered a more tempered view: "The trade shock caused a large change in behavior that resulted in that large drag due to a larger trade deficit. However, the economy did not slide into recession in Q1 2025." 
He expects a recession more likely by midyear, citing a $140 billion inventory swing that temporarily padded GDP by 2.25 percentage points.
Robin Brooks, a senior fellow at the Brookings Institution, echoed concerns about the unusual nature of the trade dynamics, calling the current environment "a huge natural experiment," with ballooning imports and swelling inventories reflecting a widespread effort to front-run tariffs.
<h3 class="wp-block-heading">Trump Responds: &#8216;This Is Biden&#8217;s Stock Market, Not Trump&#8217;s&#8217;</h3>
"This is Biden's Stock Market, not Trump's. I didn't take over until January 20th," Trump wrote on social media X, shortly after the GDP release.
Trump denied that his trade policies were responsible for the weak GDP figures, attributing the slowdown to the economic legacy of President Joe Biden. 
"This will take a while, has nothing to do with tariffs, only that he left us with bad numbers," Trump posted. 
"But when the boom begins, it will be like no other. Be patient!!!"
<h3 class="wp-block-heading">Top Premarket Gainers In The S&amp;P 500</h3>
<ul>
<li>Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) up 7.5% to $43.7</li>
<li>Trane Technologies plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>) up 6.3% to $375.6</li>
<li>Seagate Technology Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) up 5.9% to $86.4</li>
<li>Live Nation Entertainment, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) up 5.6% to $139.7</li>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) up 5.5% to $273.5</li>
</ul>
<h3 class="wp-block-heading">Top Premarket Decliners In The S&amp;P 500</h3>
<ul>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) down 19.3% to $29.1</li>
<li>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) down 12.8% to $119.6</li>
<li>Starbucks Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) down 10.0% to $76.4</li>
<li>Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) down 8.4% to $15.9</li>
<li>Garmin Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRMN#NYSE">GRMN</a>) down 8.1% to $187.5</li>
</ul>
By 8:52 a.m. ET, according to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data, the stocks falling most over the past 30 minutes of premarket trading included:
<ul>
<li>AppLovin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) down 6.2% to $242.0</li>
<li>Apollo Global Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) down 3.6% to $133.1</li>
<li>Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) down 3.5% to $220.8</li>
<li>Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) down 3.3% to $95.0</li>
<li>KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) down 3.0% to $111.0</li>
<li>Eaton Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) down 2.5% to $283.1</li>
<li>Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) down 2.4% to $111.4</li>
<li>Southern Copper Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>) down 2.2% to $87.5</li>
<li>Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) down 2.1% to $34.5</li>
<li>Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) down 2.1% to $312.0</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45098912/caterpillar-faces-lower-q1-results-but-projects-flat-sales-in-2025-or-slight-decline-with-tariff-headwinds">Caterpillar Warns Of $250 Million To $350 Million Tariff Hit After Q1 Profit Miss</a></li>
</ul>
Photo by Dilok Klaisataporn via Shutterstock

Analyst Color

Equities

Macro Economic Events

Econ #s

Economics

Tech

ETFs

FSLR

GRMN

NCLH

PLTR

SBUX

SCCO

SHOP

SMCI

TEAM

Recession Odds Spike, Wall Street Tumbles As Q1 GDP Surprisingly Contracts: 'Be Patient,' Trump Responds

Zuanic &amp; Associates analyst Pablo Zuanic reiterates Village Farms Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) from Overweight to Overweight.

Zuanic & Associates Reiterates Overweight on Village Farms Intlto Overweight

AC Immune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIU#NASDAQ">ACIU</a>) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.20) by 5 percent. This is unchanged from the same period last year. The company reported quarterly sales of $1.10 million which beat the analyst consensus estimate of $300.67 thousand by 266.19 percent.

Earnings Beats

Earnings Misses

ACIU

AC Immune Q1 EPS $(0.21) Misses $(0.20) Estimate, Sales $1.10M Beat $300.67K Estimate

Genius Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) reported quarterly losses of $(1.03) per share. This is unchanged from the same period last year. The company reported $7.91 million in sales this quarter. This is a 65.69 percent decrease over sales of $23.06 million the same period last year.

Genius Gr FY GAAP EPS $(1.03), Same YoY, Sales $7.91M Down From $23.06M YoY

Elon Musk's xAI is under fire in Memphis for deploying several methane gas turbines allegedly without permits at its <a href="https://www.benzinga.com/news/24/06/39199007/elon-musks-xai-to-take-on-tech-giants-microsoft-google-and-openai-with-planned-memphis-supercomputer">supercomputer site</a>. With growing public concern about air pollution and a lack of transparency about the operations, a crucial health department hearing is set to take place this Friday.
What Happened: xAI set up operations at a former Electrolux factory in southwest Memphis last summer to power its "Colossus" supercomputer with portable methane turbines. According<a href="https://www.theguardian.com/technology/2025/apr/24/elon-musk-xai-memphis"> to</a> the Guardian, the Southern Environmental Law Center recently shared that 35 turbines were brought in, but without air permits. 
Thermal images now reveal that 33 of them are running, even though Mayor Paul Young claimed that only 15 are active, the report said.
xAI's AI chatbot Grok is fueled by these turbines, and Musk has already <a href="https://www.benzinga.com/tech/25/03/44208284/elon-musks-xai-acquires-1-million-square-foot-property-in-memphis-for-supercomputer-expansion">purchased another 1 million sq ft site</a> to expand their operations.
xAI did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
See Also: <a href="https://www.benzinga.com/personal-finance/25/04/45055568/elon-musk-said-hed-give-6-billion-to-end-world-hunger-if-the-un-could-explain-how-they-did-but-he-didnt-give-them-a-dime">Elon Musk Said He&#8217;d Give $6 Billion to End World Hunger If the UN Could Explain How — They Did, But He Didn&#8217;t Give Them a Dime</a>
Why It Matters: The facility is situated in a historically Black area already impacted by industrial pollution and rising rates of cancer and asthma. State Rep. Justin Pearson, speaking <a href="https://www.democracynow.org/2025/4/25/elon_musk_xai_memphis_tennessee">to</a> Democracy Now, said: "We're talking about 17.2 tons of formaldehyde being released into our air, over 130 tons of nitrogen oxide—making them a bigger polluter than the Memphis International Airport. Elected officials have a responsibility to the people—not to billionaires misusing their power." Keshan Pearson, executive director of Memphis Community Against Pollution, called the project a "human rights violation."
Meanwhile, thousands of residents received fliers from a group called "Facts Over Fiction," claiming that the turbines are low-emission and EPA-regulated. However, the Guardian reports that neither the EPA nor the local health department has issued permits.
Mayor Paul Young has suggested funneling tax revenue from xAI to fund local projects, but critics like Pearson argue that this doesn't make up for the immense health impact.
Earlier, Musk's company <a href="https://www.benzinga.com/news/25/04/44725803/musks-xai-aims-for-1-million-gpus-in-memphis-but-can-the-citys-grid-handle-a-27b-ai-power-surge">requested 300 megawatts from Memphis Light, Gas and Water</a>, raising questions about the city&#8217;s ability to supply these huge amounts of power without compromising operations. 
Read Next: <a href="https://www.benzinga.com/news/25/04/45063781/elon-musk-reacts-after-ray-dalio-warns-of-us-decline-says-china-has-already-surpassed-america-as-global-consumption-leader">Elon Musk Reacts After Ray Dalio Warns Of US Decline, Says China Has Already Surpassed America As Global Consumption Leader</a>
Image Via Shutterstock

Elon Musk's xAI Faces Backlash In Memphis For Allegedly Running Methane Turbines Without Permits

Truist Securities analyst Bill Chappell downgrades Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENTA#NASDAQ">CENTA</a>) from Buy to Hold and lowers the price target from $40 to $35.

Downgrades

CENTA

Truist Securities Downgrades Central Garden & Pet to Hold, Lowers Price Target to $35

XPO Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) reported first-quarter financial results before the market open on Wednesday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/pressreleases/25/04/g45095387/xpo-reports-first-quarter-2025-results">from the quarter</a>.
<ul>
<li>Q1 Revenue: $1.95 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $1.98 billion</li>
</ul>
<ul>
<li>Q1 Adjusted EPS: 73 cents, versus estimates of 65 cents</li>
</ul>
Total revenue was down from $2.02 billion in the prior year&#8217;s quarter, primarily due to lower fuel surcharge revenue in the North American Less-Than-Truckload (LTL) segment. 
XPO generated $142 million in cash flow from operations and ended the quarter with $212 million of cash and cash equivalents on hand.
&#8220;We carried our momentum into 2025 and delivered&nbsp;first quarter&nbsp;financial results that outperformed the industry. Companywide, we reported adjusted EBITDA of&nbsp;$278 million&nbsp;and adjusted diluted EPS of&nbsp;$0.73, while operating more efficiently,&#8221; said Mario Harik, CEO of XPO.
&#8220;Our plan is driving results, with a long runway for margin expansion, supported by superior service and high-return investments in our network. We&#8217;re executing to achieve years of outperformance, regardless of the freight market environment.&#8221;
XPO executives are currently discussing the quarter on a conference call that kicked off at 8:30 a.m. ET.
XPO Price Action: <a href="http://benzinga.com/quote/xpo">XPO shares</a> were up 6.74% at $104.00 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45098912/caterpillar-faces-lower-q1-results-but-projects-flat-sales-in-2025-or-slight-decline-with-tariff-headwinds">Caterpillar Warns Of $250 Million To $350 Million Tariff Hit After Q1 Profit Miss</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/Perfectti">Miguel Perfectti</a>/Shutterstock.

XPO Reports Q1 Earnings, Shares Move Higher: 'Our Plan Is Driving Results'

Lanvin Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LANV#NYSE">LANV</a>) reported quarterly losses of $(1.50) per share. This is a 41.51 percent decrease over losses of $(1.06) per share from the same period last year. The company reported $350.72 million in sales this quarter. This is a 23.94 percent decrease over sales of $461.12 million the same period last year.

LANV

Lanvin Gr Hldgs FY GAAP EPS $(1.50) Down From $(1.06) YoY, Sales $350.72M Down From $461.12M YoY

Raymond James analyst David Feaster maintains Five Star (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSBC#NASDAQ">FSBC</a>) with a Outperform and lowers the price target from $35 to $31.

FSBC

Raymond James Maintains Outperform on Five Star, Lowers Price Target to $31

NextNRG, Inc. ("NextNRG" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXXT#NASDAQ">NXXT</a>), a pioneer in AI-driven energy innovation—transforming how energy is produced, managed, and delivered through its advanced Utility Operating System, smart microgrid technology, wireless EV charging, and on-demand mobile fuel delivery solutions— today announced the expansion of its mobile fueling operations into Oklahoma, further extending its national footprint and advancing its recurring revenue strategy.

NXXT

NextNRG Expands Mobile Fueling Operations Into Oklahoma

<ul>
<li>TSLA</li>
<li>GLD</li>
<li>AMZN</li>
<li>SMCI</li>
<li>NVDA</li>
<li>META</li>
<li>BULL</li>
<li>SNAP</li>
<li>GOOGL</li>
<li>ADP</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

AMZN

BULL

GOOGL

NVDA

SNAP

TSLA

Top 10 Trending Stocks On WallStreetBets As Of April 30, 2025 (Via Swaggy Stocks)

XYLO

Xylo Technologies Says Charging Robotics Installs Wireless EV Charging System In Robotic Parking Facilities

American Tower Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMT#NYSE">AMT</a>) reported better-than-expected first-quarter <a href="https://www.benzinga.com/quote/AMT/earnings">financial results on Tuesday</a>.
American Tower reported first-quarter revenue of $2.56 billion, beating analyst estimates of $2.54 billion, according to estimates from Benzinga Pro. The company also reported adjusted funds from operations (AFFO) of $2.75 per share, beating estimates of $2.58 per share.
"Together with the resilient demand we're seeing for our portfolio of assets, we remain focused on enhancing the quality of our earnings through active portfolio management, organizational and operational efficiency, disciplined capital allocation and a strong balance sheet, positioning us to better navigate ongoing macroeconomic uncertainty while continuing to meet our customers' critical connectivity needs," said Steven Vondran, CEO of American Tower.
American Tower said it expects total property revenue in 2025 to be between $9.97 billion and $10.12 billion. The company also raised its full-year AFFO guidance from a range of $10.31 to $10.50 to a new range of $10.35 to $10.54 per share, versus estimates of $10.39 per share.
American Tower shares gained 4.8% to close at $221.33 on Tuesday.
These analysts made changes to their price targets on American Tower following earnings announcement.
<ul>
<li>UBS analyst Batya Levi maintained American Tower with a Buy rating and raised the price target from $245 to $250.</li>
<li>Raymond James analyst Ric Prentiss maintained American Tower with a Strong Buy rating and raised the price target from $231 to $251.</li>
</ul>
Considering buying AMT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="572" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30091149/image-236-1024x572.png" alt="" class="wp-image-894945" style="width:566px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30091149/image-236-1024x572.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30091149/image-236-300x167.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30091149/image-236-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/30091149/image-236.png 1107w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a> </li>
</ul>
Photo via Shutterstock

These Analysts Boost Their Forecasts On American Tower Following Q1 Upbeat Results

Press Releases

Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025

Mersana Therapeutics to Present at Upcoming Investor Conferences

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results

Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress

Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting

Comments

Mersana Therapeutics

ニュース

最新ニュース Mersana Therapeutics (NASDAQ:MRSN) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル